Latest Ratios: P/E Ratio 28.7x · EV/EBITDA 21.8x · ROE 20.6%. (1998–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $37.0B | $41.6B | $37.9B | $30.6B | $41.5B | $48.3B | $31.9B | $24.1B | $21.1B | $22.2B | $14.3B |
| Enterprise Value | $38.6B | $43.1B | $40.2B | $31.7B | $43.2B | $49.6B | $32.8B | $25.1B | $20.6B | $21.5B | $13.9B |
| P/E Ratio → | 28.70 | 32.03 | 29.42 | 24.67 | 33.10 | 39.97 | 44.39 | 22.48 | 66.79 | 32.40 | 31.12 |
| P/S Ratio | 5.33 | 5.98 | 5.82 | 4.48 | 6.06 | 7.65 | 5.97 | 4.67 | 4.29 | 4.96 | 3.41 |
| P/B Ratio | 5.53 | 6.17 | 6.43 | 5.23 | 7.82 | 8.97 | 6.54 | 5.07 | 4.61 | 4.59 | 3.38 |
| P/FCF | 32.15 | 36.08 | 27.62 | 20.76 | 40.65 | 37.31 | 39.72 | 27.85 | 23.14 | 31.10 | 21.92 |
| P/OCF | 23.76 | 26.66 | 21.66 | 17.27 | 31.63 | 32.56 | 34.58 | 23.59 | 19.37 | 24.95 | 18.08 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 6.21 | 6.17 | 4.65 | 6.31 | 7.85 | 6.14 | 4.86 | 4.19 | 4.81 | 3.32 |
| EV / EBITDA | 21.85 | 24.41 | 23.02 | 19.58 | 22.34 | 29.73 | 28.40 | 21.30 | 18.50 | 20.39 | 16.18 |
| EV / EBIT | 26.10 | 27.88 | 24.84 | 22.14 | 27.22 | 34.42 | 35.62 | 25.29 | 20.18 | 24.39 | 22.65 |
| EV / FCF | — | 37.44 | 29.25 | 21.53 | 42.33 | 38.27 | 40.86 | 29.03 | 22.65 | 30.17 | 21.33 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 52.4% | 52.4% | 54.3% | 50.7% | 54.4% | 53.9% | 53.1% | 54.3% | 54.7% | 53.9% | 52.3% |
| Operating Margin | 21.3% | 21.3% | 22.9% | 19.8% | 23.6% | 21.3% | 15.8% | 18.2% | 18.4% | 18.8% | 14.6% |
| Net Profit Margin | 18.8% | 18.8% | 19.8% | 18.1% | 18.3% | 19.1% | 13.5% | 20.7% | 6.4% | 15.3% | 10.9% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 20.6% | 20.6% | 22.0% | 22.2% | 23.5% | 23.6% | 14.9% | 23.0% | 6.7% | 15.1% | 10.9% |
| ROA | 10.6% | 10.6% | 11.4% | 11.6% | 11.8% | 11.9% | 7.5% | 11.9% | 3.7% | 8.4% | 6.0% |
| ROIC | 13.5% | 13.5% | 14.7% | 14.5% | 17.8% | 16.3% | 11.0% | 14.3% | 16.4% | 15.7% | 12.0% |
| ROCE | 14.5% | 14.5% | 15.6% | 15.1% | 18.3% | 15.7% | 10.9% | 12.8% | 12.4% | 12.0% | 9.2% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.50 | 0.50 | 0.61 | 0.47 | 0.52 | 0.51 | 0.48 | 0.51 | 0.39 | 0.42 | 0.45 |
| Debt / EBITDA | 1.90 | 1.90 | 2.05 | 1.69 | 1.43 | 1.64 | 2.04 | 2.04 | 1.61 | 1.91 | 2.21 |
| Net Debt / Equity | — | 0.23 | 0.38 | 0.20 | 0.32 | 0.23 | 0.19 | 0.22 | -0.10 | -0.14 | -0.09 |
| Net Debt / EBITDA | 0.89 | 0.89 | 1.29 | 0.71 | 0.89 | 0.75 | 0.80 | 0.87 | -0.40 | -0.63 | -0.45 |
| Debt / FCF | — | 1.36 | 1.64 | 0.78 | 1.68 | 0.96 | 1.14 | 1.18 | -0.49 | -0.94 | -0.59 |
| Interest Coverage | 13.81 | 13.81 | 16.84 | 15.09 | 18.90 | 17.79 | 11.79 | 13.42 | 13.61 | 11.16 | 8.56 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.96 | 1.96 | 2.09 | 2.61 | 2.03 | 2.22 | 2.33 | 1.53 | 3.29 | 3.30 | 3.85 |
| Quick Ratio | 1.52 | 1.52 | 1.57 | 1.97 | 1.47 | 1.74 | 1.84 | 1.21 | 2.74 | 2.85 | 3.28 |
| Cash Ratio | 0.76 | 0.76 | 0.70 | 0.99 | 0.57 | 0.92 | 0.98 | 0.66 | 1.92 | 2.12 | 2.42 |
| Asset Turnover | — | 0.55 | 0.55 | 0.63 | 0.65 | 0.59 | 0.55 | 0.55 | 0.58 | 0.53 | 0.54 |
| Inventory Turnover | 3.22 | 3.22 | 3.00 | 3.27 | 3.01 | 3.51 | 3.48 | 3.47 | 3.49 | 3.59 | 3.76 |
| Days Sales Outstanding | — | 78.12 | 74.23 | 68.96 | 74.89 | 67.70 | 70.96 | 65.75 | 57.64 | 59.09 | 54.81 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 0.8% | 0.7% | 0.7% | 0.9% | 0.6% | 0.5% | 0.7% | 0.9% | 0.9% | 0.8% | 1.0% |
| Payout Ratio | 21.6% | 21.6% | 21.3% | 21.4% | 19.9% | 19.5% | 30.9% | 19.2% | 60.4% | 24.9% | 32.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 3.5% | 3.1% | 3.4% | 4.1% | 3.0% | 2.5% | 2.3% | 4.4% | 1.5% | 3.1% | 3.2% |
| FCF Yield | 3.1% | 2.8% | 3.6% | 4.8% | 2.5% | 2.7% | 2.5% | 3.6% | 4.3% | 3.2% | 4.6% |
| Buyback Yield | 1.1% | 1.0% | 3.0% | 1.9% | 2.7% | 1.6% | 1.5% | 3.0% | 2.0% | 0.9% | 3.0% |
| Total Shareholder Yield | 1.9% | 1.7% | 3.8% | 2.7% | 3.3% | 2.1% | 2.2% | 3.9% | 2.9% | 1.6% | 4.1% |
| Shares Outstanding | — | $284M | $291M | $296M | $300M | $307M | $312M | $318M | $325M | $326M | $329M |
Cyclical instrument demand volatility
According to current market data, Agilent trades at a forward P/E of 22.46, which suggests that investors are pricing in a premium for the company's recurring revenue model relative to more cyclical industrial peers, despite the inherent volatility in its capital equipment sales cycle.
The current P/E of 29.76 and PEG ratio of 2.02 indicate that the market expects sustained earnings expansion, likely driven by the high-margin CrossLab service segment. This valuation appears to be a middle ground between pure-play life science disruptors and broader industrial technology firms, suggesting a balanced market view on Agilent's growth-versus-value profile.
Based on reported financial figures, Agilent's ROIC has hovered between 2.8% and 4.1% over the last ten quarters, which indicates that the company is currently struggling to generate returns on invested capital that significantly exceed its cost of capital in the current macroeconomic environment.
The modest ROIC trend suggests that while the company maintains strong gross margins, the heavy investment in R&D and the integration of past acquisitions may be diluting overall capital efficiency. Investors should monitor whether the company can improve asset utilization, as current returns appear lower than those of specialized peers like Mettler-Toledo.
As reported in recent quarterly filings, Agilent's cash conversion cycle remains elevated at 123 days in 2026Q2, primarily driven by a high days-inventory-outstanding metric of 116 days, which suggests that the company is carrying significant inventory to mitigate potential supply chain disruptions in its instrument manufacturing.
The persistent length of the cash conversion cycle highlights the capital-intensive nature of the business, where inventory management is critical to maintaining service levels. While this provides a buffer against supply shocks, it also ties up significant liquidity that could otherwise be deployed toward share repurchases or strategic R&D initiatives.
Based on the most recent quarterly disclosures, Agilent maintains a current ratio of 2.10, which provides a robust liquidity cushion that appears sufficient to navigate potential downturns in laboratory capital expenditure cycles without requiring additional external financing or compromising its ongoing research and development commitments.
The quick ratio of 1.62 further confirms that the company's liquidity is not overly dependent on the liquidation of inventory, which is a positive indicator given the potential for technological obsolescence in the genomics segment. This liquidity profile supports the company's ability to maintain its dividend and share buyback programs even during periods of revenue lumpiness.
As noted in industry analysis, the P/E ratio is frequently misapplied to Agilent because it fails to account for the high proportion of deferred revenue and recurring service income, which provides a more stable earnings quality than the headline P/E multiple would otherwise suggest.
Investors should instead focus on EV/EBITDA or free cash flow yields, as these metrics better capture the underlying cash-generating power of the CrossLab ecosystem. Relying solely on P/E can lead to an underestimation of the company's value during periods where instrument sales are cyclical but service revenue remains consistently high.
Includes 30+ ratios · 28 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying A stock.
Agilent Technologies, Inc.'s current P/E ratio is 28.7x. The historical average is 26.2x. This places it at the 52th percentile of its historical range.
Agilent Technologies, Inc.'s current EV/EBITDA is 21.8x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 17.8x.
Agilent Technologies, Inc.'s return on equity (ROE) is 20.6%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 14.3%.
Based on historical data, Agilent Technologies, Inc. is trading at a P/E of 28.7x. This is at the 52th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Agilent Technologies, Inc.'s current dividend yield is 0.76% with a payout ratio of 21.6%.
Agilent Technologies, Inc. has 52.4% gross margin and 21.3% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
Agilent Technologies, Inc.'s Debt/EBITDA ratio is 1.9x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.